Male hormonal contraception

  title={Male hormonal contraception},
  author={Paul B. Cornia and Bradley D Anawalt},
  journal={Expert Opinion on Emerging Drugs},
  pages={335 - 344}
Although women have traditionally shouldered the responsibility of contraception, up to a third of couples worldwide employ a male form of contraception (e.g., condoms or vasectomy). Some women are unable to use hormonal contraception; vasectomy is best considered irreversible; and long-term use of condoms is associated with a relatively high failure rate (pregnancy). Thus, a need exists for a safe, effective, reversible, well-tolerated male hormonal contraceptive agent. Two large multi-centre… Expand
Deficiency of SPAG16L Causes Male Infertility Associated with Impaired Sperm Motility1
It is concluded that SPAG16L is essential for sperm flagellar function, and the sperm defect is consistent with the motility phenotype of the Pf20 mutants of Chlamydomonas, but morphologically different in that the mutant algal axoneme lacks the central apparatus. Expand


Contraceptive efficacy of a depot progestin and androgen combination in men.
The first male contraceptive efficacy study using a prototype depot androgen/progestin combination demonstrates high contraceptive efficacy with satisfactory short-term safety and recovery of spermatogenesis. Expand
Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception.
T implants provide adequate spermatogenic suppression in approximately 70% of Caucasian men, a rate comparable to intramuscular T injections but with minimal side effects; and, the inclusion of a type 2 5alpha-reductase inhibitor does not enhance sperMatogenic suppression. Expand
A review of androgen-progestin regimens for male contraception.
It has been 40 years since the administration of steroids to women to prevent pregnancy was approved in many countries and finally the development of reversible hormonal contraceptives for men seemsExpand
Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations.
A multi-centre study to assess men's attitudes to proposed novel hormonal methods of contraception suggests that the emerging emphasis that men should have greater involvement in family planning will be substantiated when appropriate contraceptive methods become available. Expand
Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception.
Although only 5 of 11 volunteers reached the target sperm counts (<3 million/mL), the study shows that a self-applicable hormonal male contraceptive could be developed. Expand
Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
It is concluded that with the dosages of Nal-Glu and T used in this study, the addition of GnRH antagonist to a high-dose T regimen does not increase the ability of T to suppress spermatogenesis in healthy men. Expand
Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
Combination treatment with NETE showed suppression of spermatogenesis comparable with results using testosterone esters in combination with GnRH antagonists or cyproterone acetate, but had more favorable injection intervals and better efficacy. Expand
Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
It is concluded that combination hormonal therapy with T plus a progestogen might offer a reversible male contraceptive approach with a more rapid onset of action and more reliable induction of both azoospermia and severe oligOSpermia than T alone. Expand
An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
This study documents the high efficacy of TU in combination with NET and confirms that this dose and mode of application is as effective as the previously reported regimen containing 1000 mg TU + 200 mg NETE im every 6 wk. Expand
Would women trust their partners to use a male pill
A survey of women attending family planning clinics in Scotland, China and South Africa should dispel the myth that women would not trust their partners to use a 'male pill' reliably and illustrates the potential market for the method. Expand